BPTF Protein Emerges as Key Target to Overcome Hormone Therapy Resistance in ER+ Breast Cancer
Key Insights
Researchers at Cold Spring Harbor Laboratory (search) identified BPTF (search) protein as a critical factor in hormone therapy resistance for estrogen receptor-positive breast cancer (search), which represents 75% of all breast cancer (search) cases.
BPTF (search) knockout in mouse models maintained hormone receptor positivity throughout tumor progression and restored sustained susceptibility to tamoxifen treatment.
The discovery suggests targeting BPTF (search) could reprogram resistant tumor cells back into a hormone-dependent state, offering new therapeutic possibilities for patients who no longer respond to conventional hormone therapies.
Researchers at Cold Spring Harbor Laboratory (search) (CSHL) have identified a promising new target to combat hormone therapy resistance in estrogen receptor (search)-positive (ER+) breast cancer (search), potentially transforming treatment outcomes for the 75% of breast cancer patients diagnosed with this subtype. The study, led by CSHL Associate Professor Camila dos Santos, reveals that the protein BPTF (search) plays a pivotal role in driving treatment resistance and tumor aggressiveness.
BPTF's Role in Treatment Resistance
BPTF (search), or Bromodomain PHD Finger Transcription Factor, regulates chromatin remodeling and gene transcription, influencing cell growth and differentiation. While previous studies had shown that knocking out BPTF could slow tumor growth, pharmaceutical interest waned because it did not prevent tumor formation entirely. However, dos Santos's team took a more nuanced approach to understanding BPTF's function.
By crossbreeding established murine ER+ breast cancer (search) models with BPTF (search) knockout strains, the researchers made a remarkable discovery: tumors retained their hormone receptor positivity throughout progression—something never observed before in any mouse model. This biological consistency allowed the team to test tamoxifen efficacy under BPTF-deficient conditions.
Breakthrough in Hormone Sensitivity
The results were striking. Tumors in BPTF (search)-deficient models exhibited significant and sustained susceptibility to tamoxifen treatment. What differentiated this model was that tumors sustained their reliance on estrogen receptor (search) signaling without drifting towards hormone independence, a typical pathway leading to therapy resistance in conventional models.
Graduate student Dhivyaa Anandan emphasized that "deciphering tumor heterogeneity, growth patterns, and metastatic behaviors was critical to uncovering these insights—affirming that nuanced investigation often reveals therapeutic avenues that remain invisible in more reductive models."
Experimental Validation Across Multiple Systems
The research team validated their findings using advanced organoid cultures, human breast cancer (search) cell lines, and genetically engineered mouse models that recapitulate hormone therapy resistance. Across these sophisticated systems, the abrogation of BPTF (search) synergized with tamoxifen treatment to restore hormone sensitivity, inducing tumor growth arrest.
Mechanistic Understanding
BPTF (search)'s impact likely lies in its chromatin remodeling functions that alter transcriptional landscapes governing estrogen receptor (search) expression and downstream signaling networks. By influencing histone modifications or nucleosome positioning, BPTF may facilitate tumor cell plasticity and adaptive resistance. Disabling BPTF may disrupt these epigenetic programs, restricting tumor cells from rewiring their signaling pathways to evade hormone therapies.
Clinical Implications
The implications for clinical management of ER+ breast cancer (search) are far-reaching. Current hormone therapies, while initially effective, provide only temporary reprieve for many patients due to the evolution of resistant clones. Targeting BPTF (search) could "reprogram" resistant tumor cells back into a hormone-dependent state, essentially repositioning cancer cells along a vulnerability that current therapies can exploit.
From a translational perspective, pharmacological inhibitors of BPTF (search) or strategies to diminish its expression could be developed as adjuvant treatments alongside tamoxifen and other selective estrogen receptor (search) modulators. This combinatorial approach would potentially enhance patient outcomes by maintaining hormone therapy sensitivity and preventing metastatic dissemination.
Broader Therapeutic Potential
Beyond breast cancer (search), this research highlights the therapeutic potential of targeting transcription factors and chromatin remodelers—often-overlooked players in oncogenesis that critically modulate cancer cell identity and drug responsiveness. As the research community pioneers novel epigenetic drugs, insights from the dos Santos lab provide conceptual and experimental foundations for next-generation cancer therapies.
The discovery that BPTF (search) suppression retains ER+ identity and reinstates hormone therapy sensitivity represents a significant advance in addressing breast cancer (search) metastasis and resistance. By integrating sophisticated genetic models, in vitro cultures, and human tumor studies, this research bridges fundamental biology and clinical application, setting the stage for innovative interventions that could transform patient trajectories.